For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Public ClinicalTrials.gov record NCT00037180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Randomized, Double-Blind, Multicenter Trial Of Celecoxib Vs Placebo For The Prevention Of Diarrhea Associated With CPT-11/5fu/LV Chemotherapy In Patients With Previously Untreated Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.
Study identification
- NCT ID
- NCT00037180
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 212 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2002
- Primary completion
- Not listed
- Completion
- Dec 31, 2002
- Last update posted
- Sep 28, 2008
2002 – 2003
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36685 | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| Pfizer Investigational Site | Port Saint Lucie | Florida | 34952 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60631 | — |
| Pfizer Investigational Site | Saint Joseph | Missouri | 64507 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63136 | — |
| Pfizer Investigational Site | Buffalo | New York | 14215 | — |
| Pfizer Investigational Site | Williamsville | New York | 14221 | — |
| Pfizer Investigational Site | Altoona | Pennsylvania | 16601 | — |
| Pfizer Investigational Site | Puyallup | Washington | 98372 | — |
| Pfizer Investigational Site | Yakima | Washington | 98902 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Neoplasm Metastasis trials
Other public records listing Neoplasm Metastasis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Recruiting
- NCT05614739: FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 Recruiting
- NCT07218380: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract Recruiting
- NCT07213804: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer Recruiting
- NCT07174336: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Recruiting
- NCT07114601: A Study of LY4257496 in Participants With Cancer (OMNIRAY) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00037180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2008 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00037180 live on ClinicalTrials.gov.